Abstract: A probiotic composition for improving an effect of a chemotherapeutic drug of Gemcitabine on inhibiting pancreatic cancer is disclosed in the present disclosure. The probiotic composition comprises an effective amount of Lactobacillus paracasei GMNL-133, an effective amount of Lactobacillus reuteri GMNL-89, and a pharmaceutically acceptable carrier, wherein the Lactobacillus paracasei GMNL-133 was deposited in the China Center for Type Culture Collection on Sep. 26, 2011 under an accession number CCTCC NO. M 2011331, and the Lactobacillus reuteri GMNL-89 was deposited in the China Center for Type Culture Collection on Nov. 19, 2007 under an accession number CCTCC NO. M 207154. A method for improving the effect of the chemotherapeutic drug of Gemcitabine on inhibiting pancreatic cancer is further disclosed in the present disclosure.

Abstract: A probiotic composition of improving memory and learning ability is disclosed. The probiotic composition comprises Lactobacillus acidophilus GMNL-185 and Lactobacillus rhamnosus GMNL-680, wherein the Lactobacillus acidophilus GMNL-185 was deposited in the China Center for Type Culture Collection in Wuhan, China on Nov. 3, 2017 under an accession number CCTCC NO. M 2017764, and the Lactobacillus rhamnosus GMNL-680 was deposited in the China Center for Type Culture Collection in Wuhan, China on Nov. 3, 2017 under an accession number CCTCC NO. M 2017766, wherein a ratio of a number of bacteria of the Lactobacillus acidophilus GMNL-185 to a number of bacteria of the Lactobacillus rhamnosus GMNL-680 is 1:1.

Abstract: A composition with Lactobacillus paracasei and a method to treat nasopharyngeal carcinoma through induction of pyroptosis or cell cycle arrest; Lactobacillus paracasei GMNL-653 or heat-killed whole-bacterial liquids thereof are taken as effective ingredients for inhibiting proliferations of nasopharyngeal carcinoma cells or reducing a probability of nasopharyngeal carcinoma development through pyroptosis or cell cycle arrest instead of the mechanism of apoptosis.

Abstract: A method for preventing or treating oral cancer includes administering a composition comprising Lactobacillus paracasei or a supernatant of the heat-killed Lactobacillus paracasei. A composition that contains an active ingredient with anti-oral cancer effect. The active ingredient is Lactobacillus paracasei GMNL-346 or the supernatant of the heat-killed GMNL-346. The deposition number of the Lactobacillus paracasei GMNL-346 is BCRC 910953 or CCTCC M 2019983.

Abstract: A probiotic composition for improving an effect of a chemotherapeutic drug of Gemcitabine on inhibiting pancreatic cancer is disclosed in the present disclosure. The probiotic composition comprises an effective amount of Lactobacillus paracasei GMNL-133, an effective amount of Lactobacillus reuteri GMNL-89, and a pharmaceutically acceptable carrier, wherein the Lactobacillus paracasei GMNL-133 was deposited in the China Center for Type Culture Collection on Sep. 26, 2011 under an accession number CCTCC NO. M 2011331, and the Lactobacillus reuteri GMNL-89 was deposited in the China Center for Type Culture Collection on Nov. 19, 2007 under an accession number CCTCC NO. M 207154. A method for improving the effect of the chemotherapeutic drug of Gemcitabine on inhibiting pancreatic cancer is further disclosed in the present disclosure.

Abstract: A method for preventing or treating oral cancer, including administering a composition comprising Lactobacillus paracasei or a supernatant of the heat-killed Lactobacillus paracasei. A composition that contains an active ingredient with anti-oral cancer effect. The active ingredient is Lactobacillus paracasei GMNL-346 or the supernatant of the heat-killed GMNL-346, and the deposition number of the Lactobacillus paracasei GMNL-346 is BCRC 910953 or CCTCC M 2019983.